参麦注射液对慢性肺心病缓解期的临床和免疫指标的影响

目的：观察参麦注射液对慢性肺悯病缓解期的临床和免疫指标的影响。方法：采用参麦注射液静滴，每天５０ｍｌ，共２周，观察其对生肺心病组解期病人临床症状（乏力、胸闷、气短、心悸等）１体征（紫绀、肺部湿Ｌｕｏ音）和血液体液免疫指标（ＩｇＭ、ＩｇＡ、ＩｇＧ、ＩｇＥ，及细胞免疫指标活性Ｅ花结试验、Ｔ淋巴细胞转化试验、Ｔ淋巴细胞及其亚类检测如ＣＤ３、ＣＤ４、ＣＤ８、ＣＤ５６、ＣＤ４／ＣＤ８的影响。结果：与对照治疗

Observation on clinical and immunological effects of Shenmai Injection in treating patients with chronic pulmonary heart disease in remission phase

Objective:To observe the effects of Shengmai Injetion in treating patients with chronic pulmonary heart disease in remission phase. Methods:In addition to conventional treatment (controls,n =16) ,patients in treatment group(n = 32)were also given intravenous dripping 50 ml Shengmai Injection qd for 2 weeks. The clinical symproms of hypodynami-a, chest stuffiness, dyspnea, palpitation were recorded and immune function parameters of IgM, IgA, IgG, IgE, active E rosette forming rate, T lymphocyte transforming rate,CD3, CD4. CD8, CD56,CD4/CD8 were determined before and after treatment. Results: As compared with controls,in patients of treatment group,hypodynamia, dyspnea and palpitation improve significantly two weeks after treatments the abnormally up-regulated IgG, IgA,IgE were down-regulated, while the abnormally down-regulated active E rosette forming rate, T lymphocyte transforming rate, CD3 ,CD4,CD56 ,CD4/CD8 were upregulated. Conclusion:Shengmai Inj. is a promising drug for treatment of chronic pulmonary heart disease in remission phase with benificial effects on the improvement of clinical symptoms and immune function.